Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

F15 genoplade gratis Axonics SNM-system klinisk undersøgelse

10. november 2026 opdateret af: Axonics, Inc.

Prospektiv, ikke-randomiseret, multicenter klinisk evaluering af det genopladelige Axonics SNM-system (model 4101)

Multicenter, prospective, non randomized, single arm evaluation of patients with overactive bladder (OAB) and/or fecal incontinence (FI) employing the Axonics recharge free SNM System.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

A clinical evaluation to comply with new European Medical Device Regulations (EU MDR) guidelines. Multicenter, prospective, non-randomized, single arm study for OAB and/or FI to assess the safety and performance of the Food and Drug Administration (FDA) approved Axonics recharge free sacral neuromodulation (SNM) System, INS Model 4101. The product is currently marketed under the name F15.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

144

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Birmingham, Det Forenede Kongerige, B15 2TH
        • Queen Elizabeth Hospital
      • Bristol, Det Forenede Kongerige, BS105NB
        • Bristol Urological Institute
      • London, Det Forenede Kongerige, W1G 8PH
        • University College London Hospital
      • Sheffield, Det Forenede Kongerige, S5 7AU
        • Northern General Hospital
    • Connecticut
      • Waterford, Connecticut, Forenede Stater, 06385
        • Hartford Healthcare
    • Florida
      • Bradenton, Florida, Forenede Stater, 34205
        • Florida Gulf Clinical Research
      • Jacksonville, Florida, Forenede Stater, 32216
        • East Coast Institute of Research
      • Naples, Florida, Forenede Stater, 34109
        • Florida Bladder Institute
    • Georgia
      • Macon, Georgia, Forenede Stater, 31201
        • Atrium Health
    • Minnesota
      • Coon Rapids, Minnesota, Forenede Stater, 55433
        • Minnesota Urology
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68114
        • Adult Pediatric Urology & Urogynecology
    • New York
      • New York, New York, Forenede Stater, 10032
        • Columbia University Medical Center
    • Oregon
      • Portland, Oregon, Forenede Stater, 97225
        • The Oregon Clinic
    • South Carolina
      • Myrtle Beach, South Carolina, Forenede Stater, 29572
        • Southern Shores Urogynecology
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Houston Colon
      • Rotterdam, Holland
        • Erasmus Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. 18 years or older
  2. Primary indication of overactive bladder (OAB) (urinary urgency incontinence (UUI)/ urinary frequency (UF)) or fecal incontinence (FI) who are not candidates for, or who have failed conservative treatment
  3. Willing and capable to provide written informed consent and agrees to comply with specified evaluations at clinical investigational sites and attend all follow-up assessments for up to 1 year.

Exclusion Criteria:

  1. Any significant medical condition that is likely to interfere with procedures, device operation, or likely to confound evaluation of endpoints (exclusion of neurological conditions such as multiple sclerosis)
  2. Any psychiatric or personality disorder that is likely to interfere with procedures at the discretion of the participating physician; this may include poor understanding or compliance with requirements
  3. Previously underwent an external sacral neuromodulation (SNM) trial and was deemed a non-responder or was previously implanted with a sacral neuromodulation device and did not get therapeutic benefit (a non-responder)
  4. History of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone
  5. A female who is breastfeeding
  6. A female with a positive urine pregnancy test

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Single Arm - Treatment Groups separated into OAB and FI

Treatment Arm separated into 2 cohorts:

  1. Overactive Bladder (OAB)
  2. Fecal incontinence (FI)

Safety and performance/effectiveness assessment of the recharge free Axonics SNM System (Model 4101 in participants with overactive bladder (OAB) or fecal incontinence (FI).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Performance/Effectiveness - Improvement in Quality of Life scoring (OAB)
Tidsramme: 3 months

International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life (ICIQ-OABqol): questions in each subscale are scored by a summed range of 0 to 100, with a higher score indicating better quality of life. Overall score ≥ 10 points from baseline to follow-up is indicative of a clinically meaningful improvement.

3 months
Performance/Effectiveness - Improvement in Fecal Incontinence Survey
Tidsramme: 3 months

Cleveland Clinic Florida - Fecal Incontinence Score (CCF-FIS): includes 5 items (solid, liquid, gas, wears pad and lifestyle alteration) and 5 frequencies (never = 0, rarely = 1, sometimes = 2, usually = 3, always = 4). Scores range from 0 for full continence to 20 for complete incontinence. A higher score is indicative of the severity of fecal incontinence.

3 months
Adverse event reporting (Safety)
Tidsramme: 3 months

Device-related, procedure-related and all serious adverse events

3 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Performance/Effectiveness - Improvement in Quality of Life scoring (OAB)
Tidsramme: 1 year

International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life (ICIQ-OABqol): questions in each subscale are scored by a summed range of 0 to 100, with a higher score indicating better quality of life. Overall score ≥ 10 points from baseline to follow-up is indicative of a clinically meaningful improvement.

1 year
Performance/Effectiveness - Improvement in Fecal Incontinence Survey
Tidsramme: 1 year

Cleveland Clinic Florida - Fecal Incontinence Score (CCF-FIS): includes 5 items (solid, liquid, gas, wears pad and lifestyle alteration) and 5 frequencies (never = 0, rarely = 1, sometimes = 2, usually = 3, always = 4). Scores range from 0 for full continence to 20 for complete incontinence. A higher score is indicative of the severity of fecal incontinence.

1 year
Performance/Effectiveness - Improvement in Quality of Life Survey (FI)
Tidsramme: 3 months, 6 months, 1 year

Fecal Incontinence Quality of Life (FIQoL): includes four different subscales: lifestyle, coping/behavior, depression/self-perception and embarrassment. Subscale scores range from 1 to 5, with 1 indicating lower functional status of qualify of life.

3 months, 6 months, 1 year
Adverse event reporting (Safety)
Tidsramme: 1 year

Device-related, procedure-related and all serious adverse events

1 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Prof. Bertil Blok, MD, PhD, Erasmus Medical Center
  • Studieleder: Gita Ghadimi, OD, Boston Scientific Corporation

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. december 2023

Primær færdiggørelse (Anslået)

1. december 2026

Studieafslutning (Anslået)

1. december 2027

Datoer for studieregistrering

Først indsendt

13. december 2023

Først indsendt, der opfyldte QC-kriterier

28. december 2023

Først opslået (Faktiske)

2. januar 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 105-0108

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .